These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25885530)

  • 1. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.
    Wagner MJ; Amodu LI; Duh MS; Korves C; Solleza F; Manson SC; Diaz J; Neary MP; Demetri GD
    BMC Cancer; 2015 Mar; 15():175. PubMed ID: 25885530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
    Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
    Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
    Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
    BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of treatment patterns among recurrent/metastatic soft tissue sarcoma patients who consulted medical oncologists in Japan.
    Nakano K; Ae K; Matsumoto S; Takahashi S
    J Orthop Sci; 2019 Nov; 24(6):1081-1087. PubMed ID: 31447093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
    Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
    BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
    Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
    Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma.
    Tsuchiya H; Tomita K; Yamamoto N; Mori Y; Asada N
    Anticancer Res; 1998; 18(5B):3651-6. PubMed ID: 9854472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
    J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up after primary treatment of soft tissue sarcoma of extremities: impact of frequency of follow-up imaging on disease-specific survival.
    Chou YS; Liu CY; Chen WM; Chen TH; Chen PC; Wu HT; Chiou HJ; Shiau CY; Wu YC; Liu CL; Chao TC; Tzeng CH; Yen CC
    J Surg Oncol; 2012 Aug; 106(2):155-61. PubMed ID: 22297812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO).
    Hartmann JT; Issels RD; Nicolo KS; Grünwald V; Hertenstein B; Papesch E; Krause S; Sturm I
    Invest New Drugs; 2015 Oct; 33(5):1115-22. PubMed ID: 26163339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
    Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
    Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
    Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
    Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.